Pharmaceutical initiatives to combat atherosclerosis - What to do with the good, the bad, and the ugly lipoproteins

Seminars in Vascular Surgery

Volumn 15, Issue 4, 2002, Pages 204-215

  Samson, Russell H ^a,b  

^a Mote Vascular Foundation   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FOLIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; PSYLLIUM HYDROCOLLOID; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ALOPECIA; ARTERY DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; FLATULENCE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIMB ISCHEMIA; LIPID METABOLISM; LIVER DYSFUNCTION; MEMORY DISORDER; MUSCLE INJURY; MYALGIA; MYOSITIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; REVIEW; RHABDOMYOLYSIS; SUSTAINED RELEASE PREPARATION;

EID: 0036918691     PISSN: 08957967     EISSN: None     Source Type: Journal    
DOI: 10.1053/svas.2002.36256     Document Type: Review

References (110)

1. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA, 282:2340-2346, 1999
2. Marchioli R, Marfisi RM, Carcini F, et al: Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 156:1158-1172, 1996
3. Ford CS, Crouse JR 3rd, Howard G, et al: The role of plasma lipids in carotid bifurcation atherosclerosis. Ann Neurol 17:301-303, 1985
4. van Merode T, Hick P, Hoeks PG, et al: Serum HDL/total cholesterol ratio and blood pressure in asymptomatic atherosclerotic lesions of the cervical carotid arteries in men. Stroke 16:34-38, 1985
5. Wilson PW, Hoeg JM, D'Agostino RB, et al: Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 337:516-522, 1997
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
7. Gordon T, Castelli WP, Hjartland MC, et al: High density lipoprotein as a protective factor against coronary artery disease. The Framingham Study. Am J Med 62:707-714, 1977
8. Stampfer MJ, Krauss RM, Ma J, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996
9. Miller BD, Alderman EL, Haskell WL, et al: Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94:2146-2153, 1996
10. Cantin B, Gagnon F, Moorjani S, et al: Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 31:519-525, 1998
11. Cobbaert C, Jukema JW, Zwinderman AH, et al, on behalf of the Regression Growth Evaluation Statin Study (REGRESS) Study Group: Modulation of Lp(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. J Am Coll Cardiol 30:1491-1499, 1997
12. Cheng SW, Ting AC: Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 22:124-129, 2001
13. Ballantyne CM, Grundy SM, Oberman A, et al: Hyperlipidemia: Diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 85:2089-2112, 2000
14. Avins AL, Neuhaus JM: Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 160:1937-1944, 2000
15. Rosenson RS: Myocardial injury the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933-940, 1993
16. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 89:763-771, 2001
17. Mauriello A, Sangiorgi G, Palmieri G, et al: Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation 101:744-750, 2000
18. Freedman DS, Williamson DF, Gunter EW, et al: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637-644, 1995
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
20. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996
21. Manninen V, Tenkanen L, Koskinen P, et al: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 85:37-45, 1992
22. Muldoon MF, Manuck SB, Mendelsohn AB, et al: Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials. BMJ 322:11-15, 2001
23. Hebert PR, Gaziano JM, Chan KS, et al: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278:313-321, 1997
24. Bucher HC, Griffith LE, Guyatt GH: Effect of HMGCoA reductase inhibitors on stroke. A meta-analysis of randomized controlled trials. Ann Intern Med 128:89-95, 1998
25. Byington RP, Davis BR, Plehn JF, et al, for the PPP investigators: Reduction in stroke events with pravastatin. The Prospective Pravastatin Pooling (PPP) project. Circulation 103:387-392, 2001
26. Crouse JR, Byington RP, Hoen HM, et al: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 157:1305-1310, 1997
27. Thompson GR, Hollyer J, Waters DD: Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 6:386-388, 1995
28. Rosenson RC, Tangney CC: Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279:1643-1650, 1998
29. Jukema JW, Bruschke AVG, van Boven AJ, et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995
30. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274-1275, 1995
31. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445, 1998
32. Furberg CD, Byington RP, Crouse JR: Pravastatin, lipids, and major coronary events. Am J Cardiol 73:1133-1134, 1994
33. Miettinen TA, Pyorala K, Olsson AG, et al, for the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96:4211-4218, 1997
34. Blake GJ, Ridker PM: Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med 1:161-165, 2000
35. Rosenson RS: Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 156:1278-1284, 1996
36. Harper CR, Jacobson TA: New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 159:1049-1057, 1999
37. Hebert PR, Gaziano JM, Chan KS, et al: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials. JAMA 278:313-321, 1997
38. Eastern Stroke and Coronary Heart Disease Collaborative Research Group: Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352:1801-1807, 1998
39. Sacco RL, Benson RT, Kargman DE, et al: High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA 285:2729-2735, 2001
40. Butowski PF, Winder AF: Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolemia: Data from the UK Lipid Clinics Programme. Eur Heart J 19:1328-1333, 1998
41. Andrade SE, Walerks AM, Gottlieb LK, et al: Discontinuation of antihyperlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 332:1125-1131, 1995
42. Pedersen TR, Berg K, Cook TJ, et al: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156:2085-2092, 1996
43. Larsen ML, Illingworth DR: Drug treatment of dyslipoproteinemia. Med Clin North Am 78:225-245, 1994
44. Levy RI, Troendle AJ, Fattu JM: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87:III45-53, 1993
45. Illingworth DR, Stein EA, Mitchel YB, et al: Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154:1586-1595, 1994
46. Sprecher DL, Abrams J, Allen JW, et al: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 120:537-543, 1994
47. Jones P, Kafonek S, Laurora I, et al, for the CURVES Investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587, 1998
48. Brown AS, Bakker-Arkema RG, Yellen L, et al: Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 32:665-672, 1998
49. Pan HY, DeVault AR, Swites BJ, et al: Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 48:201-207, 1990
50. Sprecher DL, Abrams J, Allen JW, et al: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 120:537-543, 1994
51. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164, 2001
52. Ness GC, Zhao Z, Lopez D: Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch Biochem Biophys 325:242-248, 1996
53. Conde K, Vergara-Jimenez M, Krause BR, et al: Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 37:2372-2382, 1996
54. Ness GC, Chambers CM, Lopez D: Atorvastatin action involves diminished recovery of hepatic HMG CoA reductase activity. J Lipid Res 39:75-84, 1998
55. Marz W, Scharnagl H, Abletshauser C, et al: Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 103:1942-1948, 2001
56. Kastelein JJ, Isaacsohn JL, Ose L, et al: Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 86:221-223, 2000
57. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al: Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 276:128-133, 1996
58. Dart A, Jerums G, Nicholson G, et al: A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80:39-44, 1997
59. Halstenson CE, Triscari J, DeVault A, et al: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 32:124-132, 1992
60. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33, 1988
61. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998
62. Weismantel D: What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterollowering agents? J Fam Pract 50:927-928, 2001
63. Mevacor (Lovastatin, MSD): United States Food and Drug Administration Package Insert. Merck, Sharp and Dohme, West Point, PA
64. Zocor (Simvastatin, MSD). United States Food and Drug Administration Package Insert. Merek, Sharp and Dohme, West Point, PA
65. Pravachol (Pravastatin Sodium). United States Food and Drug Administration Package Insert. Bristol Meyers Squibb, Princeton, NJ
66. Lescol (Fluvastatin Sodium). Sandoz Pharmaceuticals Corporation, Product Circular, East Hanover, NJ
67. Davignon J, Roederer G, Montigny M, et al: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 73:339-345, 1994
68. Yoshimura N, Oka T, Okamoto M: The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 53:94-99, 1992
69. Kobashigawa JA, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995
70. Schrama YC, Hene RJ, de Jonge N, et al: Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients. Transplantation 66:1175-1181, 1998
71. Glueck CJ, Oakes N, Speirs J, et al: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 70:1-9, 1992
72. Rosenson RS: Gemfibrozil-lovastatin associated myalgia. Am J Cardiol 71:497, 1993
73. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis with lovastatin-gemfibrozil combination therapy. JAMA 264:71-75, 1990
74. Wiklund O, Bergman M, Bondjers G, et al: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 94:13-20, 1993
75. Rosenson RS, Frauenheim WA: Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 74:499-500, 1994
76. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al: Safety and efficacy of long-term statin-fibrate combination in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608-613, 1997
77. Weismantel D: What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterollowering agents? J Fam Pract 50:927-928, 2001
78. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996
79. Bjerre LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110:716-723, 2001
80. Freeman DJ, Norrie J, Sattar N, et al: Pravastatin and the development of diabetes mellitus. Evidence of a protective treatment effect in the West of Scotland Coronary Prevention study. Circulation 103:357-362, 2001
81. Edwards CJ, Russell RG, Spector TD: Statins and bone: Myth or reality? Calcif Tissue Int 69:63-66, 2001
82. Sposito AC, Mansur AP, Coelho OR, et al: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 83:1497-1499, 1999
83. Scott HD, Laake K: Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 4:CD003160, 2001
84. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2:600-604, 1984
85. Staels B, Dallongeville J, Auwerx J, et al: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093, 1998
86. Vu-Dac N, Schoonjans K, Kosykh V, et al: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750, 1995
87. Berthou L, Duverger N, Ammanuel F, et al: Opposite regulation of human versus mouse apoprotein A-I by fibrates in human apolipoprotein-A-I transgenic mice. J Clin Invest 97:2408-2416, 1996
88. Jin F-Y, Kamanna VS, Chuang M-Y, et al: Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler Thromb Vasc Biol 16:1052-1062, 1996
89. Jones PH, Pownall HJ, Patsch W, et al: Effect of gemfibrozil on levels of lipoprotein(a) in type II hyperlipoproteinemia subjects. J Lipid Res 37:1298-1308, 1996
90. Nordt TK, Kornas K, Peter K, et al: Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type I induced by insulin and its precursors. Circulation 95:677-683, 1997
91. Westphal S, Dierkes J, Luley C: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:39-40, 2001
92. Dierkes J, Westphal S, Luley C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354:219-220, 1999
93. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
94. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 151:1873-1874, 1991
95. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis with lovastatin-gemfibrozil combination therapy. JAMA 264:71-75, 1990
96. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al: Safety and efficacy of long-term statin-fibrate combination in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608-613, 1997
97. Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155-162, 1998
98. Grundy SM, Mok HY, Zech L, et al: Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22:24-36, 1981
99. Illingworth DR, Stein EA, Mitchel YB, et al: Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154:1586-1595, 1994
100. Philipp CS, Cisar LA, Saidi P, et al: Effect of Niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. Am J Cardiol 82:697-699, 1998
101. Probstfield JL, Hunninghake DB: Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 154:1557-1559, 1994
102. Guyton JR, Goldberg AC, Kreisberg RA, et al: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82:737-743, 1998
103. Etchason JA, Miller TD, Squires RW, et al: Niacin-induced hepatitis: A potential side effect with low-dose timerelease niacin. Mayo Clin Proc 66:23-28, 1991
104. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723-726, 1990
105. Pasternak RC, Kolman BS: Unstable myocardial ischemia after the initiation of niacin therapy. Am J Cardiol 67:904-906, 1991
106. Garg R, Malinow M, Pettinger M, et al: Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J 138:1082-1087, 1999
107. Shepherd J, Packard CJ, Morgan HG, et al: The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 33:433-444, 1979
108. Davidson MH, Dillon MA, Gordon B, et al: Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159:1893-1900, 1999
109. Insull W Jr, Toth P, Mullican W, et al: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 76:971-982, 2001
110. Spence JD, Huff MW, Heidenheim P, et al: Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med 123:493-499, 1995